ORIGINAL CONTRIBUTION. Epilepsy in Patients With Angelman Syndrome Caused by Deletion of the Chromosome 15q11-13

ORIGINAL CONTRIBUTION Epilepsy in Patients With Angelman Syndrome Caused by Deletion of the Chromosome 15q11-13 Kette D. Valente, MD, PhD; Célia P. Koiffmann, PhD; Cíntia Fridman, PhD; Mônica Varella, PhD; Fernando Kok, MD, PhD; Joaquina Queiroz Andrade, MD, PhD; Rosi M. Grossmann, MD, PhD; Maria Joaquina Marques-Dias, MD, PhD Background: Angelman syndrome (AS) is a neurogenetic disorder characterized by severe mental retardation, speech disorder, stereotyped jerky movements, and a peculiar behavioral profile, with a happy disposition and outbursts of laughter. Most patients with AS present with epilepsy and suggestive electroencephalographic patterns, which may be used as diagnostic criteria. Objective: To study epilepsy and response to treatment in a series of patients with AS determined by deletion. Design: Parent and caregiver interview and medical record review. Setting: Epilepsy Center at the University of São Paulo. Patients: Nineteen patients with AS determined by deletion of chromosome 15q11-13. Main Outcome Measures: Epilepsy severity, epilepsy evolution, and response to antiepileptic drug treatment. Results: All patients with AS in this group had generalized epilepsy, and 10 (53%) also had partial epilepsy. Main seizure types were atypical absences and myoclonic and tonic-clonic seizures. Mean age at onset was 1 year 1 month. Epilepsy aggravated by fever occurred in 10 patients (53%) and status epilepticus in 16 (84%). Eighteen patients (95%) had previous or current history of daily seizures, of which 14 (64%) had disabling seizures. Multiple seizure types were observed in 13 patients (53%). History of refractory epilepsy was reported in 16 patients (84%). Parents reported improvement, characterized by decrease in seizure frequency or seizure control, at the mean age of 5.3 years. Therefore, most of these patients had a period of refractory epilepsy; however, improvement occurred during late childhood and puberty. The best therapeutic response was obtained with valproic acid alone or in association with phenobarbital or clonazepam. Epilepsy was aggravated by carbamazepine, oxcarbazepine, and vigabatrin. Conclusions: Patients with AS with deletion have epilepsy with early onset and stereotyped electroclinical profile regarding seizure type, severity, and response to antiepileptic drug treatment. Another feature of AS is the age-related improvement, even in refractory cases, during late childhood and puberty. These characteristics are not specific to this syndrome but, when inserted in the proper clinical context, may anticipate diagnosis. We believe that AS should be considered a differential diagnosis in developmentally delayed infants with severe, generalized, cryptogenic epilepsy; however, a proper electroclinical delineation of each genetic group is mandatory. Arch Neurol. 2006;63:122-128 Author Affiliations: Laboratory of Clinical Neurophysiology, Institute and Department of Psychiatry (Dr Valente), Center for the Study of Human Genome, Institute and Department of Biology (Drs Koiffmann and Varella), Department of Legal Medicine (Dr Fridman), Department of Neurology, Child Neurology Unit (Drs Kok, Andrade, Grossmann, and Marques-Dias), and Department of Pediatrics (Dr Marques-Dias), University of São Paulo, São Paulo, Brazil. ANGELMAN SYNDROME (AS) IS a neurogenetic disorder characterized by severe mental retardation, speech disorder, stereotyped jerky movements, and a peculiar behavioral profile, with a happy disposition and outbursts of laughter. Eighty percent to 90% of these patients present with epilepsy and suggestive electroencephalographic patterns, which may be used as diagnostic criteria and become important when the phenotype is not suggestive enough, as in infants. Other features, such as hyperactivity, hypopigmentation, ataxia, sleep disorder, and peculiar facial traits (macrostomia, wide-spaced teeth, prognathism, and macrognathism), have variable occurrence, ranging from 20% to 80%. 1 To date, 4 genetic mechanisms have been described for this syndrome. The known genetic mechanisms are deletion (del[15q11-13]), 2-4 paternal uniparental disomy, 5 imprinting center abnormality, 6 and UBE3A mutations, 7,8 all of which affect the maternal chromosome 15q11-13, a known imprinted region. Maternal del (15q11-13), characterized by the loss of 1 part of the chromosome, occurs in 75% to 80% of patients. 9 Uniparental disomy or the inheritance of 2 alleles with the same parental origin, in this case from the father, is detected in 1% to 3% of patients. 10 Imprinting center abnormalities occur in 2% to 5% of cases, 11 and in this case, although there is biparental inheritance of chromosome 15, both chromosomes have a paternal expression owing 122

to a mutation in the imprinting center. Approximately 8% of all patients with AS have a UBE3A mutation that determines loss of function of the gene encoding a ubiquitin protein ligase. The remaining 12% to 15%, despite the absence of a detectable genetic mechanism, are considered to have AS, and diagnosis is performed on clinical and electroencephalographic (EEG) grounds. Recurrence risk is distinct for each group. 12 Therefore, identification of patients with AS is mandatory because of implications in genetic counseling. Singh et al 13 emphasized the scarcity of articles that provide a meticulous classification of epilepsy and epileptic syndromes, according to International League Against Epilepsy classification systems. 14 The importance of such detailed electroclinical descriptions lies in identifying specific epileptic syndromes associated with particular chromosomal aberrations as well as providing regions of interest for genetic research. The first studies designed to study epilepsy in AS were published in the 1990s, 15,16 usually encompassing a small number of patients. Consequently, many controversies exist regarding seizure type and its evolution, as well as the best therapeutic approaches. Additionally, characterization of epilepsy in AS has been determined by studies with small sample sizes that combine patients determined by distinct genetic mechanisms into 1 group for analysis. We studied and followed up 19 patients with AS caused by 15q11-13 deletion, aiming to evaluate whether epilepsy in AS is stereotyped enough to represent a specific profile that could be of practical importance for diagnosis of AS in this group. METHODS Forty-five consecutive patients (73% female and 27% male, aged 6 months to 22 years) with a presumptive clinical diagnosis of AS were referred to the Epilepsy Center at the University of São Paulo duringa4-yearperiodforclinicalandelectroencephalographicevaluations. A geneticist (C.P.K.) and a child neurologist (K.D.V.) separately examined all patients, using criteria determined by the Consensus for Diagnostic Criteria of AS. 1 The inclusion criterion for this study was genetic confirmation of chromosome 15 deletion. Of all patients referred and tested, we confirmed 26 (69% female) as having AS. Nineteen patients (73%) were determined by maternal deletion of chromosome 15q11-13, 3 (12%) had a paternal uniparental disomy, and 4 (15%) did not have a detectable genetic mechanism, but their clinical phenotype was supportive of diagnosis according to evaluations performed by both a geneticist and a child neurologist involved in this project. EPILEPSY CHARACTERIZATION We obtained a detailed history of epilepsy from parents and caregivers and corroborated this information by checking medical records and previous examination results (EEGs and video EEGs) and by personal contact with referring physicians. The following information was collected: (1) presence of epilepsy, (2) age at epilepsy onset, (3) seizure type at onset and during follow-up, (4) history of severe epilepsy, (5) status epilepticus (SE), (6) history of refractory epilepsy, and (7) occurrence of isolated seizures and/or febrile seizures. Video EEG monitoring (6-48 hours; mean, 8 hours) was performed in 18 patients, 15 (58%) with deletion, to detect subtle seizures that went either unnoticed or unreported by parents and/or caregivers. Seizure Table 1. Seizure Type at Onset Patient Age at Onset Initial Seizure Triggering Factor 1 2y6mo Complex partial 2 1y2mo Simple partial with motor phenomenon (hemiclonic) 3 5 mo Atypical absence status Hyperthermia 4 2y2mo Generalized tonic Hyperthermia 5 10 mo Myoclonic 6 2 y Atypical absences 7 9 mo Generalized tonic 8 8 mo Atypical absences and myoclonic 9 2 y 11 mo Complex partial 10 1y2mo Simple partial with motor phenomenon (hemiclonic) 11 8 mo Myoclonic 12 5 mo Myoclonic Hyperthermia 13 4 mo Myoclonic 14 6 mo Myoclonic 15 4 mo Generalized tonicclonic Hyperthermia 16 2y2mo Simple partial with Hyperthermia motor phenomenon (hemiclonic) 17 4 mo Atypical absences 18 6 mo Complex partial 19 11 mo Atypical absences types were determined by history corroborated by past medical records and video EEG and were classified according to guidelines of the Commission on Classification and Terminology of the International League Against Epilepsy. 14 DNA ANALYSIS All patients had their conditions diagnosed with a methylation test, and genetic mechanisms were characterized by microsatellite analysis. 17 Patients with normal results on both tests were screened for UBE3A mutations in exons 7 through 16, representing the coding region of the gene. 8 No mutations were found in the UBE3A gene. Patients did not undergo imprinting center abnormality mutation screening, since the combination of methylation and microsatellite analyses was not suggestive. Association of methylation pattern of AS and normal inheritance of 15q11-13 alleles (maternal and paternal), shown by microsatellite analysis, was the parameter used to detect an imprinting center abnormality mutation case. RESULTS PREVALENCE AND SEIZURE TYPE Epilepsy occurred in 22 patients (85%) (19 with deletion and 3 with negative genetic study results). In 1 patient with uniparental disomy, epilepsy occurred as an isolated generalized tonic-clonic episode (no recurrence). All patients with deletion had epilepsy. All 19 patients with deletion and epilepsy had generalized seizures, and 10 (53%) had partial seizures (Table 1 and Table 2). All patients had more than 1 123

Table 2. Characteristics of Epilepsy in Patients With Angelman Syndrome Determined by Deletion During Follow-up Patient/ Age Seizure Types During Follow-up Age at the Last Seizure Current Seizures 1/6 y 11 mo Occipital lobe evolving to CP, GTC 4 y 11 mo 2/7y4mo Hemiclonic aggravated by fever, AA, Partial motor with fever, AA Mcl, SE with SP (hemiclonic) 3/3y8mo AA,GTCaggravated by fever, GTC GTC aggravated by fever and AA occurring as SE 4/13y7mo GTCaggravated by fever, AA, GTC Sporadic generalized tonic and GTC occurring as SE 5/12y3mo Mcl, GT aggravated by fever, GT occurring as SE Myoclonic 6/12y5mo AA,Mcl, GTC, CP, 8y3mo Mcl occurring as SE 7/12y8mo GTC, AA, Mcl, Mcl and GT occurring as SE 10 y 8/3y9mo Mcl, AA, GTC aggravated by fever, SP (hemiclonic) occurring as SE aggravated by fever AA and Mcl with fever 9/4 y 11 mo CP, AA occurring as SE 3y2mo 10/6y2mo SPwith motor phenomenon, AA, AA SP with motor phenomenon occurring as SE 11/6 y* Mcl, AA, GTC, AA occurring as SE NA NA 12/8 y 11 mo Mcl occasionally aggravated by fever, 3y9mo SP with motor phenomenon, AA, AA occurring as SE 13/7y5mo Mcl, AA, AA occurring as SE AA 14/3y6mo Mcl, AA, AA occurring as SE 15/7y3mo AA,Mcl, SP with motor phenomenon Partial motor and AA during fever with secondary generalization, AA and Mcl occasionally aggravated by fever occurring as SE 16/6y8mo CP,Mcl, SP with motor phenomenon Myoclonic aggravated by fever, SP with motor phenomenon and Mcl occurring as SE 17/5y1mo AA,Mcl, GTC aggravated by fever, AA occurring as SE during fever, GTC, Mcl AA occurring as SE 18/6y1mo Mcl, AA, CP with secondary 5y2mo generalization 19/8 y AA, GTC aggravated by fever 5y4mo Abbreviations: AA, atypical absences; CP, complex partial seizures; GT, generalized tonic seizures; GTC, generalized tonic-clonic seizures; Mcl, myoclonic seizures; NA, not applicable; SE, status epilepticus; SP, simple partial seizures. *Death during follow-up. seizure type, classified as atypical absences in 16 patients (84%), myoclonic in 13 (68%), generalized tonicclonic or tonic in 12 (63%), simple partial with motor phenomena in 6 (32%), complex partial in 5 (26%), and myoclonic-astatic in 2 (11%). We registered seizures in 13 (87%) of the 15 patients who underwent video EEGs (1-4 per patient). Atypical absences occurred in 7, myoclonic seizures in 3, tonicclonic seizures in 2, atonic seizures in 1, and unnoticed occipital lobe seizures with head deviation in 1. These events were unnoticed by parents or reported as periods of decreased contact with environment in 9 patients. Six patients had SE, which was characterized as atypical absence status in 5 and myoclonic status in 1. AGE AT ONSET Mean age at onset was 1 year 1 month (range, 4 months to 2 years 11 months). First seizures were atypical absences and myoclonic seizures in 5 (26%) each and simple partial, complex partial, and generalized tonic-clonic or tonic seizures in 3 (14%) each (Table 1). In 18 patients, epilepsy onset preceded diagnosis of AS, based on clinical phenotype, from 5 months to 5 years 9 months (mean, 2 years 8 months; median, 2 years 2 months). EPILEPSY AGGRAVATED BY FEVER Five patients (26%) had their first seizure during a febrile episode. During follow-up, 10 (53%) had epilepsy aggravated by fever. In 8 patients (36%), seizure worsening by high or even moderate temperatures was recurrent, which led to SE in 7 patients. STATUS EPILEPTICUS Sixteen patients (84%) had SE, of which 7 cases were recurrent. Atypical absence SE (8 patients) and myo- 124

clonic SE (3 patients) were characterized by longlasting periods of impaired contact accompanied by frequent head dropping or excessive trembling. These episodes were recognized as periods of cognitive decline and in 7 patients led to a misguided metabolic investigation. Introduction of carbamazepine, oxcarbazepine, and vigabatrin apparently caused (timerelated) seizure worsening, leading to SE in 5 patients. Hyperthermia was associated with SE (especially with its recurrence) in 7 children. SEVERITY AND EVOLUTIONARY ASPECTS Eighteen patients (95%) had previous or current history of daily seizures from 4 months (median, 1 year 2 months) to 10 years (median, 4 years), of which 14 (64%) had disabling seizures, which occurred from 4 months (median, 8 months) to 7 years (median, 2 years 7 months). Multiple seizure types (more than 3 different types) were observed in 13 patients (53%) up to the age of 7 years (median, 5 years 1 month). The analysis of previous and current seizures shows a tendency to present a decrease in the diversity of seizure type with age. There is a predominance of generalized seizures, especially atypical absences and myoclonic seizures, at older ages. During follow-up, we observed that patients who had spontaneous seizures have a tendency to exhibit or maintain seizures restricted to or predominantly seen during periods of fever or infection. History of refractory epilepsy was reported in 16 patients (84%). Parents reported improvement, characterized by decrease in seizure frequency or seizure control, at the mean age of 5.3 years (range, 2.0-11.5 years). However, epilepsy was totally controlled only in 7 patients (37%) at the mean age of 8 years 7 months (range, 4 years to 12 years 8 months), all of which remain under antiepileptic drug treatment. Seizure type or number of seizures was not predictive of remission or better response to antiepileptic drug treatment. ANTIEPILEPTIC DRUG TREATMENT Valproic acid improved seizure control in 18 patients undergoing either monotherapy or polytherapy, especially when associated with clonazepam (5 patients) or phenobarbital (5 patients). Phenobarbital was effective only when coadministered with valproic acid, but not in monotherapy or with other drugs. Association of valproic acid and lamotrigine was effective in 2 cases. Carbamazepine was effective only in 1 patient, and topiramate, used in 2 patients, did not improve seizure control. Additionally, ketogenic diet, used in 4 refractory cases, was effective in all. Of the 8 patients who used carbamazepine, 5 had seizure aggravation, 1 of whom had atypical absence status. In the only patient from this series who used oxcarbazepine, a prolonged and repetitive generalized tonic-clonic seizure led to hospitalization. The introduction of vigabatrin in 1 patient had a temporal relationship with the onset of myoclonic SE (Table 3). COMMENT The estimated prevalence of AS (1 in 10 000 to 12 000) 18-20 is similar to that of Rett syndrome (1 in 12 000), 21 suggesting that AS remains underdiagnosed. Better understanding of epilepsy features in AS might be helpful in changing this scenario. PREVALENCE AND SEIZURE TYPE In agreement with previous series, our work showed that epilepsy in AS ranges from 80% 1 to 90%. 22 Analysis of such a high prevalence must consider that both our study and previous studies encompass patients determined by distinct genotypes. However, there is evidence that different genetic groups may present different profiles, with distinct degrees of severity, and that a more severe form of epilepsy occurs in patients with deletion. 23 In our series, all patients with deletion had epilepsy, indicating a higher prevalence in this group, as previously demonstrated. 23,24 This finding suggests that future studies on epilepsy in AS should address these groups individually. Although seizures in AS were extensively described, the delineation of epilepsy in AS is still controversial in many aspects. All seizure types have been reported in AS, with predominance of generalized seizures, especially atypical absences 15,16,24 and myoclonic seizures. 25-27 In agreement with this, atypical absences and subtle myoclonic seizures were the most frequently observed and registered by us with video EEG but not the most frequently reported by parents, who tend to note mostly those accompanied by evident motor phenomena. Because of the high frequency of atypical absences and myoclonic seizures in these patients, we observed that video EEG was crucial to recording of nonconvulsive status, which occurs as a prolonged event that lasts weeks or months and is reported as a period of decreased contact with environments, as previously reported by Matsumoto et al. 15 Viani et al 26 reported complex partial seizures of occipital lobe origin as a frequent event, an observation not yet corroborated by others. 24,27,28 Only 1 of our patients presented with this seizure type during monitoring, and no parent reported similar events when specifically questioned. Infantile spasms are described in some chromosomal disorders, such as Down syndrome 29-32 or inv dup(15) 33-37 ; however, they were not observed in our patients, even at younger ages, and are rarely reported in AS. 15,26 Other less frequently reported seizure types are atonic, myoclonic-absence, hemigeneralized, and partial. 16,22,38 It is possible that the frequency of myoclonic seizures or even pure atonic seizures may be higher in our patients. However, one of the most challenging aspects in the study of epilepsy in children, especially those with severe cognitive impairment, is the difficulty of differentiating certain seizure types by history alone. This is a limitation of our study and of all previous work that addresses this issue. Although we analyzed seizure semiology by video EEG to avoid 125

Table 3. History of Treatment in Patients With Angelman Syndrome Determined by Deletion Patient/Age AEDs Used During Follow-up Current AED Seizure Aggravation With AEDs 1/6 y 11 mo Carbamazepine Carbamazepine 2/7y4mo Phenobarbital; phenobarbital and Valproic acid and phenobarbital carbamazepine; phenobarbital and valproic acid 3/3y8mo Phenobarbital; phenobarbital and clonazepam; phenobarbital Phenobarbital, valproic acid, and clonazepam and valproic acid 4/13y7mo Phenobarbital; valproic acid; Valproic acid and clonazepam carbamazepine and clobazam; carbamazepine and clonazepam; valproic acid 5/12y3mo Carbamazepine; phenobarbital; valproic acid Phenobarbital and valproic acid 6/12y5mo Phenobarbital; valproic acid Phenobarbital; valproic acid; valproic acid and nitrazepam 7/12y8mo Carbamazepine; carbamazepine and Valproic acid clonazepam; valproic acid and clonazepam 8/3y9mo Phenobarbital; valproic acid; clobazam Valproic acid and clobazam 9/4 y 11 mo Carbamazepine; valproic acid; clobazam Valproic acid and clobazam Atypical absence status with carbamazepine at 3y1mo 10/6y2mo Phenobarbital; phenobarbital and Valproic acid and phenobarbital carbamazepine; valproic acid 11/6 y Carbamazepine; valproic acid; clonazepam Valproic acid and clonazepam 12/8 y 11 mo Phenobarbital; phenobarbital and Valproic acid and clonazepam valproic acid; valproic acid and clobazam; KD; clonazepam 13/7y5mo Valproic acid; corticotropin; corticosteroids; KD; lamotrigine; clonazepam; topiramate Valproic acid, lamotrigine, and clonazepam 14/3y6mo Valproic acid; nitrazepam Valproic acid and nitrazepam 15/7y3mo Phenobarbital; phenytoin; carbamazepine and clonazepam; phenobarbital; valproic acid Phenobarbital and valproic acid 16/6y8mo Phenobarbital; phenobarbital and valproic acid; oxcarbazepine; KD; valproic acid; valproic acid and clonazepam Valproic acid and clobazam 17/5y1mo Phenobarbital; phenobarbital and Valproic acid and lamotrigine clonazepam; phenobarbital and clobazam; KD; vigabatrin; lamotrigine and clobazam; valproic acid and clobazam; corticosteroids; valproic acid and lamotrigine; topiramate 18/6y1mo Valproic acid Valproic acid 19/8 y Phenobarbital; phenobarbital and valproic acid; valproic acid and clonazepam Abbreviations: AED, antiepileptic drug; KD, ketogenic diet. Valproic acid, phenobarbital, and clonazepam Myoclonic status with oxcarbazepine at 3y3mo Myoclonic status with vigabatrin at 4 y misdiagnoses, this was a partial solution, since we could record only patients current seizures. AGE AT ONSET One of the most important aspects of AS is the late onset of clinical phenotype, especially the diagnostic facial traits. However, in these developmentally delayed infants, epilepsy has an early onset, 15,28,39 preceding clinical diagnosis in most patients. The atypical absences and myoclonic seizures were the most frequent seizures at onset, as reported by Matsumoto et al. 15 Laan et al 24 reported epilepsy with an occasional later onset (5 years old). In our experience, prospective family interviews instead of medical record reviews may result in identification of unreported or unnoticed subtle seizures, such as myoclonic and atypical absences, occurring earlier than surmised. EPILEPSY AGGRAVATED BY FEVER Seizure worsening during fever occurred in 53%, a high rate if compared with overall age-matched population, and similar to the rates reported by Viani et al 26 and Laan et al. 24 As in the series of Viani et al, 26 in some cases fever triggered the first seizure. Buoni et al 28 reported these events in AS related to moderate temperatures. In our patients, there was a predominance of generalized seizures during these episodes. Although febrile seizures are extensively reported as a frequent event in AS, descriptions of the seizure type aggravated by fever are scant. STATUS EPILEPTICUS Although frequently documented and reported, variations exist regarding prevalence and seizure type. Laan et al 24 reported SE in 36.1% of their patients, and Sugi- 126

moto et al 16 reported SE in 75% of patients. In our series, SE occurred in 84%, and the main seizure types were atypical absence, myoclonic seizure, and generalized tonicclonic seizure, similar to that reported by Laan et al. 24 Our high prevalence may be related to video EEG monitoring when nonconvulsive status was observed, although this was mostly not noticed by relatives or otherwise reported as a reduction in motor activity and/or cognitive impairment. Our incidence of myoclonic status was below that reported by others, 25-27 probably because some of these investigators performed polygraphic recordings and back-averaging techniques. 25,27 AGE-RELATED IMPROVEMENT Severity of epilepsy was measured by high seizure frequency, presence of injurious seizures that impaired daily activities, occurrence of multiple seizure types, and SE. Presence of disabling seizures and multiple seizure types has already been respectively reported by Laan et al 24 and Matsumoto et al. 15 We also observed frequent occurrence of daily seizures and a tendency of milder epilepsy at later ages or, less commonly, with total control. Buoni et al 28 and Laan et al 24 indicated that seizures were age dependent, as observed in our study. However, there has been some discussion as to whether seizure improvement occurs during late childhood and puberty 16,26,40 or during adulthood. 24,40,41 Epilepsy in our patients was considered severe or at least as having a period of severity, mainly during early childhood and infancy, with a decrease in seizure frequency predominantly in late childhood. In a retrospective study, Laan et al 24 reported that atypical absences and myoclonic seizures persist in adulthood but are milder, as observed in our patients. In our series, relatives often reported a period of refractoriness, followed by improvement during childhood and early puberty. Nonetheless, complete seizure control was obtained in only 37% of our patients. Minassian et al 23 stressed the importance of video EEG monitoring in detecting seizures in adults because of their sporadic nature. To date, information on adults with AS, especially focusing on epilepsy, is scarce, and larger series with adults are necessary to elucidate the evolution of epilepsy in AS. RESPONSE TO TREATMENT Nakatsu et al, 42 who studied an AS homologue region deleted in a mutant mouse (the pink-eyed cleft palate [p(cp)] mouse) reported that the genes encoding -aminobutyric acid type A (GABAA) receptor subunits 5, 3, and 3 were disrupted. This deletion led to alterations of binding properties of the GABAA receptors in the brain, providing an in vivo model system for studying GABAA receptor function in AS. Although UBE3A dysfunction is seen as the cause of AS, GABA genes may have a contributory role in the phenotype, 43,44 especially in epilepsy. It may be postulated that the good therapeutic response to valproic acid, phenobarbital, and clonazepam, regardless of seizure type, observed in our series and in parents questionnaires 45 may be determined by this GABAergic receptor deletion. Along the same lines, benzodiazepines seem to be effective, which may be related to the decrease in benzodiazepine receptor density in 60% to 80% of cases, as demonstrated by Odano et al. 46 However, vigabatrin, which is also a GABAergic drug, was not effective in these patients. The ability of vigabatrin in increasing GABA without enhancing GABAergic receptor function may be a possible explanation for its failure in AS. As with vigabatrin, we observed seizure aggravation with carbamazepine and oxcarbazepine. On the other hand, a ketogenic diet was effective in all 4 patients who tried it. Topiramate 47 and ethosuximide 48 improved epilepsy in a small series of patients who had AS with refractory epilepsy. To date, we cannot corroborate these findings because of our limited experience with these drugs in AS. SIMILARITIES WITH OTHER CHROMOSOMAL DISORDERS The occurrence of age-related refractory epilepsy with atypical absences and myoclonic seizures, worsened by fever and frequently occurring as SE, has suggested a clinical profile that may be helpful in identifying patients with AS, especially infants. However, a similar profile has been described in other chromosomal disorders, 49-51 indicating that the electroclinical picture of AS is useful only when inserted into its proper clinical context. The origin of these similarities is unknown, and theories that try to implicate GABAergic genes as a common denominator do not contemplate all syndromes involved. In conclusion, patients with AS determined by deletion present with a high prevalence of early-onset epilepsy, often severe and refractory. Seizure onset usually precedes clinical diagnosis based on phenotype and could be used as an element for earlier diagnosis. Proper characterization of epilepsy in AS may be an important diagnostic tool, since epilepsy is stereotyped with the presence of atypical absences, myoclonic seizures, epilepsy aggravated by fever, and SE during infancy and early childhood. We believe that AS should be considered as a differential diagnosis in developmentally delayed infants with severe, generalized cryptogenic epilepsy. The delineation of the electroclinical behavior in each group is important to determine possible differences among groups. Accepted for Publication: July 20, 2005. Correspondence: Kette D. Valente, MD, PhD, Department of Psychiatry, University of São Paulo, R. Jesuíno Arruda, 901/51, 04532-082 São Paulo, SP Brazil (kettevalente@msn.com). Author Contributions: Study concept and design: Valente. Acquisition of data: Valente, Koiffmann, Fridman, Varella, Kok, Andrade, and Grossmann. Analysis and interpretation of data: Valente, Koiffmann, Varella, Kok, Andrade, Grossmann, and Marques-Dias. Drafting of the manuscript: Valente. Critical revision of the manuscript for important intellectual content: Valente, Koiffmann, Fridman, Varella, Kok, Andrade, Grossmann, and Marques-Dias. Obtained funding: Valente, Koiffmann, and Marques-Dias. Administrative, technical, and material support: Valente, Fridman, Andrade, and Grossmann. Study supervision: Valente, Andrade, Grossmann, and Marques-Dias. 127

Funding/Support: Drs Valente, Fridman, Varella, and Koiffmann were supported by grants from Fundação de Amparo a Pesquisa do Estado de São Paulo, São Paulo, Brazil. REFERENCES 1. Williams CA, Angelman H, Clayton-Smith J, et al. Angelman syndrome: consensus for diagnostic criteria: Angelman Syndrome Foundation. Am J Med Genet. 1995;56:237-238. 2. Kaplan LC, Wharton R, Elias E, Mandell F, Donlon T, Latt SA. Clinical heterogeneity associated with deletions in the long arm of chromosome 15: report of 3 new cases and their possible genetic significance. Am J Med Genet. 1987; 28:45-53. 3. Knoll JH, Nicholls RD, Magenis RE, Graham JM Jr, Lalande M, Latt SA. Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion. Am J Med Genet. 1989;32:285-290. 4. Magenis RE, Brown MG, Lacy DA, Budden S, LaFranchi S. Is Angelman syndrome an alternate result of del(15)(q11q13)? Am J Med Genet. 1987;28:829-838. 5. Nicholls RD, Pai GS, Gottlieb W, Cantu ES. Paternal uniparental disomy of chromosome 15 in a child with Angelman syndrome. Ann Neurol. 1992;32:512-518. 6. Buiting K, Saitoh S, Gross S, et al. Inherited microdeletions in the Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15. Nat Genet. 1995;9:395-400. 7. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15:70-73. 8. Matsuura T, Sutcliffe JS, Fang P, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997; 15:74-77. 9. Williams CA, Gray BA, Hendrickson JE, Stone JW, Cantu ES. Incidence of 15q deletions in the Angelman syndrome: a survey of twelve affected persons. Am J Med Genet. 1989;32:339-345. 10. Engel E. Chromosome 15 uniparental disomy is not frequent in Angelman syndrome. Am J Hum Genet. 1991;49:459-460. 11. Dittrich B, Buiting K, Horsthemke B. PW71 methylation test for Prader-Willi and Angelman syndromes. Am J Med Genet. 1996;61:196-197. 12. Burger J, Buiting K, Dittrich B, et al. Different mechanisms and recurrence risks of imprinting defects in Angelman syndrome. Am J Hum Genet. 1997;61:88-93. 13. Singh R, Gardner RJ, Crossland KM, Scheffer IE, Berkovic SF. Chromosomal abnormalities and epilepsy: a review for clinicians and gene hunters. Epilepsia. 2002; 43:127-140. 14. Proposal for revised classification of epilepsies and epileptic syndromes: Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30:389-399. 15. Matsumoto A, Kumagai T, Miura K, Miyazaki S, Hayakawa C, Yamanaka T. Epilepsy in Angelman syndrome associated with chromosome 15q deletion. Epilepsia. 1992;33:1083-1090. 16. Sugimoto T, Yasuhara A, Ohta T, et al. Angelman syndrome in three siblings: characteristic epileptic seizures and EEG abnormalities. Epilepsia. 1992;33: 1078-1082. 17. Mutirangura A, Greenberg F, Butler MG, et al. Multiplex PCR of three dinucleotide repeats in the Prader-Willi/Angelman critical region (15q11-q13): molecular diagnosis and mechanism of uniparental disomy. Hum Mol Genet. 1993; 2:143-151. 18. Buckley RH, Dinno N, Weber P. Angelman syndrome: are the estimates too low? Am J Med Genet. 1998;80:385-390. 19. Kyllerman M. On the prevalence of Angelman syndrome [letter]. Am J Med Genet. 1995;59:405. 20. Petersen MB, Brondum-Nielsen K, Hansen LK, Wulff K. Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county. Am J Med Genet. 1995;60:261-262. 21. Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of pervasive developmental disorders in the British nationwide survey of child mental health. J Am Acad Child Adolesc Psychiatry. 2001;40:820-827. 22. Zori RT, Hendrickson J, Woolven S, Whidden EM, Gray B, Williams CA. Angelman syndrome: clinical profile. J Child Neurol. 1992;7:270-280. 23. Minassian BA, DeLorey TM, Olsen RW, et al. Angelman syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol. 1998;43:485-493. 24. Laan LA, Renier WO, Arts WF, et al. Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia. 1997;38:195-199. 25. Dalla Bernardina B, Fontana E, Zullini E, et al. Angelman syndrome: electroclinical features of ten personal cases. Gaslini. 1995;27(suppl 1, pt 2):75-78. 26. Viani F, Romeo A, Viri M, et al. Seizure and EEG patterns in Angelman s syndrome. J Child Neurol. 1995;10:467-471. 27. Guerrini R, De Lorey TM, Bonanni P, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol. 1996;40:39-48. 28. Buoni S, Grosso S, Pucci L, Fois A. Diagnosis of Angelman syndrome: clinical and EEG criteria. Brain Dev. 1999;21:296-302. 29. Guerrini R, Dravet C, Ferrari AR, et al. The evolution of epilepsy in the most common genetic forms with mental retardation (Down s syndrome and the fragile X syndrome). Pediatr Med Chir. 1993;15(suppl 1):19-22. 30. Stafstrom CE, Patxot OF, Gilmore HE, Wisniewski KE. Seizures in children with Down syndrome: etiology, characteristics and outcome. Dev Med Child Neurol. 1991;33:191-200. 31. Pueschel SM, Louis S, McKnight P. Seizure disorders in Down syndrome. Arch Neurol. 1991;48:318-320. 32. Silva ML, Cieuta C, Guerrini R, Plouin P, Livet MO, Dulac O. Early clinical and EEG features of infantile spasms in Down syndrome. Epilepsia. 1996;37:977-982. 33. Freitas A, Valente K, Varela MC, Fridman C, Koiffmann CP. The complexity of inv dup (15): a mild phenotype associated with heterogeneous electroclinical profile and an imprecise correlation with genotype. Epilepsia. 2003;44(suppl 9):55. 34. Buoni S, Sorrentino L, Farnetani MA, Pucci L, Fois A. The syndrome of inv dup (15): clinical, electroencephalographic, and imaging findings. J Child Neurol. 2000; 15:380-385. 35. Cabrera JC, Marti M, Toledo L, Gine R, Vazquez C. West s syndrome associated with inversion duplication of chromosome 15. Rev Neurol. 1998;26:77-79. 36. Bingham PM, Spinner NB, Sovinsky L, Zackai EH, Chance PF. Infantile spasms associated with proximal duplication of chromosome 15q. Pediatr Neurol. 1996; 15:163-165. 37. Kobayashi A, Ito M, Okada M, Yoshioka K. A case of 15p tetrasomy associated with infantile spasms [in Japanese]. No To Hattatsu. 1994;26:74-77. 38. Elia M, Guerrini R, Musumeci SA, Bonanni P, Gambardella A, Aguglia U. Myoclonic absence-like seizures and chromosome abnormality syndromes. Epilepsia. 1998;39:660-663. 39. Casara GL, Vecchi M, Boniver C, et al. Electroclinical diagnosis of Angelman syndrome: a study of 7 cases. Brain Dev. 1995;17:64-68. 40. Clayton-Smith J. Clinical research on Angelman syndrome in the United Kingdom: observations on 82 affected individuals. Am J Med Genet. 1993;46:12-15. 41. Buntinx IM, Hennekam RC, Brouwer OF, et al. Clinical profile of Angelman syndrome at different ages. Am J Med Genet. 1995;56:176-183. 42. Nakatsu Y, Tyndale RF, DeLorey TM, et al. A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature. 1993;364:448-450. 43. DeLorey TM, Handforth A, Anagnostaras SG, et al. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci. 1998;18:8505-8514. 44. DeLorey TM, Olsen RW. GABA and epileptogenesis: comparing gabrb3 genedeficient mice with Angelman syndrome in man. Epilepsy Res. 1999;36: 123-132. 45. Ruggieri M, McShane MA. Parental view of epilepsy in Angelman syndrome: a questionnaire study. Arch Dis Child. 1998;79:423-426. 46. Odano I, Anezaki T, Ohkubo M, et al. Decrease in benzodiazepine receptor binding in a patient with Angelman syndrome detected by iodine-123 iomazenil and single-photon emission tomography. Eur J Nucl Med. 1996;23:598-604. 47. Franz DN, Glauser TA, Tudor C, Williams S. Topiramate therapy of epilepsy associated with Angelman s syndrome. Neurology. 2000;54:1185-1188. 48. Sugiura C, Ogura K, Ueno M, Toyoshima M, Oka A. High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit. Neurology. 2001;57:1518-1519. 49. Laan LA, Vein AA. A Rett patient with a typical Angelman EEG. Epilepsia. 2002; 43:1590-1592. 50. Valente KD. Another Rett patient with a typical Angelman EEG. Epilepsia. 2003; 44:873-874. 51. Sgro V, Riva E, Canevini MP, et al. 4p(-) syndrome: a chromosomal disorder associated with a particular EEG pattern. Epilepsia. 1995;36:1206-1214. 128